Structure-based ensemble-QSAR model: a novel approach to the study of the EGFR tyrosine kinase and its inhibitors
Acta Pharmacologica Sinica2013Vol. 35(2), pp. 301–310
Citations Over TimeTop 13% of 2013 papers
Related Papers
- → Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?(2017)4 cited
- → Tyrosine Kinase Inhibitors in Advanced Renal Cell Carcinoma: The Evolving Treatment Paradigm(2009)4 cited
- Update on Tyrosine Kinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma(2011)
- Токсичность и эффективность тирозинкиназных ингибиторов в сочетании с химиотерапией при резистентном течении острого Ph-позитивного лимфобластного лейкоза (обзор литературы и клинический случай)(2017)
- Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Non-Small Cell Lung Cancer (NSCLC), Practical Pharmacological Aspects(2019)